Peptide evidence review

What the research actually shows about Ipamorelin

Here is the honest split. There is real human evidence that ipamorelin raises growth hormone for a short window in healthy adults, a measured biomarker effect. There is no human evidence that the pulse turns into anything you would feel: not fat loss, not muscle, not anti-aging, not any clinical benefit. Its only controlled human disease trial failed, the developer shut the program down, and it is banned in sport at all times. Almost every body-composition claim attached to it rests on rat studies, and the closest animal data on body fat point the wrong way.

The honest read

The honest read on ipamorelin is a split, and it is worth stating both halves up front. There is real human evidence that ipamorelin does one thing: it raises growth hormone for a short window. In healthy men, a single dose produces a brief, dose-related pulse of growth hormone that then fades. That is a genuine, measured effect, and it is also a biomarker moving, not a benefit you can feel. The other half of the split is the part the marketing skips: there is no human evidence that the pulse turns into anything. A higher growth-hormone reading on a lab printout is not the same as more muscle, less fat, better recovery, or a longer healthspan, and the human evidence that the pulse translates into any of those outcomes does not exist. Hold those two facts together and you have the whole compound: the biomarker is real, the benefit is unproven.

The rest of the honest read is shorter than the marketing suggests. Ipamorelin has never been approved by the FDA for anything. The only controlled human trial that tested an actual clinical outcome, in patients recovering bowel function after surgery, did not beat placebo, and the company developing it shut the program down. Every claim about bone, muscle, fat loss, and anti-aging rests on rat studies, and one of the better animal studies points the opposite way from the fat-loss pitch. And for any athlete subject to testing, ipamorelin is banned at all times.

This piece grades each claim by the strength of the evidence behind it, separates what was shown in people from what was shown in animals and cells, and surfaces the safety and regulatory status you would want before any conversation with a clinician.

What ipamorelin is and how it is thought to work

Ipamorelin is a synthetic five-amino-acid peptide. It belongs to a family called growth-hormone secretagogues, compounds that prompt the body's own pituitary gland to release growth hormone rather than supplying growth hormone directly. It works by binding the ghrelin receptor (GHS-R1a), the same receptor the hunger hormone ghrelin uses, and that binding triggers a pulse of growth-hormone release (Raun et al. 1998).

The receptor story has been worked out carefully, but it was worked out in animals and isolated cells. In cultured rat pituitary cells, ipamorelin released growth hormone with a potency and ceiling similar to the older peptide GHRP-6, and blocking experiments confirmed it acts through the ghrelin-type receptor rather than the separate growth-hormone-releasing-hormone receptor (Raun et al. 1998). Whether the downstream growth-hormone-to-IGF-1 step follows depends on context: in diabetic mice, ipamorelin raised growth hormone but IGF-1 rose only in the non-diabetic animals, because growth-hormone resistance blunted the response (Johansen et al. 2003). The pathway is real, and it is also conditional.

Ipamorelin's signature claim is selectivity. When several growth-hormone secretagogues were compared in swine, the older GHRP-6 and GHRP-2 also raised the stress hormones ACTH and cortisol, while ipamorelin raised growth hormone without meaningfully raising either, even at doses far above the level needed for the growth-hormone effect (Raun et al. 1998). That is the empirical basis for the "clean, selective, no cortisol spike" positioning you will see in marketing. Read it with the model attached: the selectivity was demonstrated in animals, and no human study has re-tested it at the same rigor. It is a reasonable laboratory finding, not a human-confirmed fact.

What the research actually shows, graded by evidence tier

Here is the split that matters most, stated plainly. Strip out the roughly twenty analytical-chemistry papers where ipamorelin is just one substance in an anti-doping urine-detection panel, and the therapeutic evidence is overwhelmingly animal. There are two genuine human therapeutic studies: one pharmacology study measuring growth-hormone release in healthy men, and one controlled disease trial that failed. Around eleven in-vivo animal studies in rats, mice, swine, and ferrets carry the rest of the load. Animal evidence outnumbers human roughly five to one, and the single human study with a real clinical endpoint was negative.

The pharmacology of ipamorelin is clean and well characterized. The clinical case in humans is one biomarker study and one failed trial. The sections below walk each use case at its own tier.

Growth-hormone release: a human biomarker, not a benefit

This is the best-supported human finding, and it is important to state exactly what it is. In a dose-escalation study in forty healthy adult men, ipamorelin given by intravenous infusion produced a dose-proportional, single growth-hormone peak about forty minutes after the dose, then declined to negligible levels (Gobburu et al. 1999). That confirms ipamorelin transiently stimulates growth hormone in people.

What it does not show is any clinical benefit. The study measured hormone levels in healthy volunteers; it did not measure body composition, strength, recovery, sleep, or any health outcome, and the subjects had nothing wrong with them to improve. A growth-hormone increase is a biomarker movement. Treating "raises growth hormone" as if it were "improves health" is the central error in how this compound is sold, and the FDA, reviewing ipamorelin, found no data supporting effectiveness for diagnosing or treating growth-hormone deficiency in children or adults by any route (FDA Pharmacy Compounding Advisory Committee).

Postoperative ileus: the one human disease trial, and it failed

Ipamorelin's lead medical indication was postoperative ileus, the sluggish return of bowel function after abdominal surgery, and the animal case for it was promising: in rodent models, ipamorelin shortened the time to first bowel movement and improved gastric emptying through a ghrelin-receptor mechanism (Venkova et al. 2009; Greenwood-Van Meerveld et al. 2012).

It did not translate. In a multicenter, double-blind, placebo-controlled phase-2 trial of 117 adults undergoing bowel resection, intravenous ipamorelin given twice daily after surgery did not significantly beat placebo on the primary endpoint, time to tolerate a solid meal, at a median of 25.3 hours versus 32.6 hours with a p-value of 0.15 (Beck et al. 2014). No efficacy was demonstrated. FDA records note that development was discontinued because of these disappointing results (FDA Pharmacy Compounding Advisory Committee). A second, larger phase-2 study completed around the same time but never posted or published results, which given the contemporaneous shutdown should be read as a completed-but-unreported trial, not as hidden evidence of benefit (ClinicalTrials.gov NCT01280344). The one time ipamorelin was tested against placebo on a real clinical outcome in people, it lost.

Bone, muscle, and anti-catabolic effects: rats only

A cluster of studies reports skeletal and muscle effects, and every one of them is in rats. Ipamorelin increased the longitudinal growth rate of bones in adult female rats but did not change total IGF-1 or the standard bone-formation markers (Johansen et al. 1999). It raised bone mineral content in young adult female rats, but a closer analysis showed the gain came from bones getting larger in size rather than denser, an important distinction, because bigger bones are not the same as stronger bones (Svensson et al. 2000). In rats given bone-thinning steroids, ipamorelin restored some bone formation and muscle force (Andersen et al. 2001), and in steroid-treated rats it partly counteracted nitrogen wasting, though explicitly less effectively than growth hormone itself (Aagaard et al. 2009).

None of this has been shown in humans. There is no human bone outcome, no human muscle outcome, and no human strength outcome for ipamorelin, and even the rodent muscle-sparing effect was weaker than the growth hormone it stimulates.

Fat loss, body composition, and "anti-aging": no human evidence, and the animal data cut the other way

This is where marketing and evidence diverge most sharply. There is no human evidence that ipamorelin reduces body fat. And the most direct animal study is a caution, not a green light: in mice, growth-hormone secretagogues including ipamorelin produced growth-hormone-independent increases in body fat, raising fat-pad weight, leptin, and food intake through the appetite-stimulating ghrelin action, while growth hormone itself reduced relative fat mass (Lall et al. 2001). In other words, the best mechanistic animal data suggest the ghrelin effect could add fat by driving appetite, the opposite of the fat-loss claim.

The "anti-aging" and "longevity" claims have no primary outcome evidence in humans or animals at all; they are extrapolations from general growth-hormone biology. Recent expert reviews classify growth-hormone-axis secretagogues like ipamorelin as investigational, with uncertain safety profiles and broad anti-doping restrictions (Villegas Meza et al. 2026; Mendias and Awan 2026; Sinha et al. 2020). When someone tells you a growth-hormone peptide reverses aging or melts fat, the honest response is that no study has tested those outcomes, and the closest animal data on fat point the wrong way.

Appetite and cachexia: the one setting where the ghrelin effect is studied as a benefit

Because ipamorelin works through the ghrelin receptor, it shares ghrelin's appetite-stimulating action, and that is the one context where this effect has been studied as a possible benefit rather than a liability. In ferrets, ipamorelin and the related drug anamorelin reduced the wasting caused by chemotherapy (Lu et al. 2024). That is an appetite and anti-wasting signal, the same mechanism that can add body fat in healthy animals. It is still animal-only for ipamorelin, and notably it is anamorelin, a different compound, that carries the actual human cachexia data. The throughline is consistent: ipamorelin's ghrelin action is real, and it points toward eating more, not toward the lean physique it is sold to produce.

Safety, side effects, and what we don't know

The honest framing on safety starts with how little human data exists. Essentially all of it comes from the single failed surgery trial, where ipamorelin was given intravenously for up to a week in sick post-surgical patients. There are no human safety data for the subcutaneous injection that compounding pharmacies and wellness clinics actually sell, which is a different route, a different exposure, and an uncharacterized risk profile (FDA Pharmacy Compounding Advisory Committee).

In that trial, ipamorelin was generally tolerated, but several effects occurred more often than with placebo: low blood potassium, insomnia, and elevated blood sugar at discharge (Beck et al. 2014). The blood-sugar signal matters, because stimulating growth hormone is expected to push toward insulin resistance and higher glucose, and the FDA, reviewing the compound, concluded there were insufficient data to rule out the glucose-intolerance and diabetes risks associated with approved growth-hormone-stimulating products (FDA Pharmacy Compounding Advisory Committee). The agency also flagged peptide-specific concerns for compounded material: immunogenic potential, self-association and aggregation, and impurity and characterization challenges.

Because no approved label exists, the contraindications can only be stated as precautions inferred from the drug class, not as established labeled warnings: active cancer, because growth-hormone and IGF-1 signaling is theoretically growth-promoting; diabetes or impaired glucose tolerance, given the hyperglycemia signal; and pregnancy or breastfeeding, where there are simply no data. There are no formal human drug-interaction studies. There is no established, evidence-based human dose, and the doses used in studies were intravenous and in a hospital setting; nothing about the way ipamorelin is marketed for at-home subcutaneous use has been tested for safety or effect in people.

There is one more practical gap that has nothing to do with the molecule and everything to do with the market. Because no approved product exists, the ipamorelin sold through clinics and online is compounded or research-grade material whose purity, identity, and concentration are not guaranteed, and the FDA specifically flagged peptide aggregation, immunogenic potential, and impurity characterization as unresolved problems for compounded ipamorelin (FDA Pharmacy Compounding Advisory Committee). You would not only be weighing a compound with thin evidence; you would be weighing a supply chain with little oversight.

FDA status and anti-doping (WADA) status

Before any efficacy claim, two facts about ipamorelin's status have to be on the table.

First, FDA status: ipamorelin has never been approved by the FDA for any use. It is sold in the United States only as a compounded product through wellness clinics and compounding pharmacies, and the FDA's Pharmacy Compounding Advisory Committee evaluated ipamorelin-related bulk substances and reached an unfavorable conclusion, finding no data supporting effectiveness, no mention in clinical guidelines, and safety concerns serious enough to flag (FDA Pharmacy Compounding Advisory Committee). The precise, current federal compounding category for ipamorelin is in flux and under active review, so we are deliberately not asserting a specific 2026 regulatory category as settled fact; the durable, verified statement is that ipamorelin is not an FDA-approved medicine and that its availability rides on compounding and research channels of uncertain and shifting regulatory status. It should never be described as a "legal supplement" or an "FDA-approved" anything.

Second, anti-doping status: ipamorelin is on the World Anti-Doping Agency Prohibited List under Section S2, the peptide-hormone and growth-factor category, in the sub-class for growth-hormone secretagogues, where it is named explicitly alongside compounds like ibutamoren and macimorelin (World Anti-Doping Agency 2026; U.S. Anti-Doping Agency). Section S2 substances are prohibited at all times, both in and out of competition. Any athlete subject to anti-doping rules who uses ipamorelin commits a violation. This is not a gray area, and it is the kind of detail that should be stated prominently for anyone who competes.

How and when to think about using ipamorelin

Vague "ask your doctor" is not useful, so here is the specific version, and for ipamorelin the specific version starts with an honest hard stop. There is no evidence-based dose, because no human trial ever established one for the way ipamorelin is actually used. The only human dosing was intravenous, in a hospital, in a trial that failed; the subcutaneous before-bed injection that clinics and communities use has never been tested in people for safety or effect. Every dose, frequency, and cycle you will see quoted comes from what clinics publish and what people report doing, not from anything validated. We are not going to hand you a protocol the evidence does not support. What we can do is lay out how to think about the decision, and report, in the next section, what is actually done, so you are deciding with open eyes rather than from a clinic's pitch.

The decision factors are the ones already on this page, lined up, and the first one is the one the marketing inverts. The upside is biomarker-grade and nothing more: ipamorelin reliably moves a number, growth hormone, for a short window, and there is no human evidence that the number moving produces fat loss, muscle, better recovery, or slower aging. You would be buying a confirmed lab-value change in pursuit of an outcome no study has shown it delivers. The long-term safety is genuinely unknown: all human safety data come from up to a week of intravenous dosing in sick post-surgical patients, the FDA flagged growth-hormone-class glucose risk and unresolved peptide-impurity concerns, and chronic stimulation of your own growth-hormone axis is not a characterized exposure. The supply is unregulated: with no approved product, the ipamorelin sold online and through clinics is compounded or research-grade material whose identity, purity, and concentration are not guaranteed. And the regulatory and sport status is settled and against use: never FDA-approved, availability riding on compounding channels of shifting status, and banned in sport at all times under WADA Section S2.

Some "when not" answers are clear enough to state plainly. If you are subject to anti-doping testing, ipamorelin is on the WADA list at all times and is detectable, so check the current status of this exact compound before you go anywhere near it, and understand the answer for a tested athlete is no. If you have diabetes, prediabetes, or any glucose problem, the growth-hormone-class tendency to raise blood sugar is a real reason to steer clear. If you have a personal or family history of cancer, the theoretical concern about stimulating the growth-hormone and IGF-1 axis is reason to steer clear. If you cannot verify what is actually in the vial with a batch-specific certificate of analysis, you are dosing an unknown. And if you are pregnant or breastfeeding, there are no data and no reason to assume any.

If, knowing all of that, you still want to understand what real-world use looks like, the next section reports it, with the risks named and without a recommendation attached.

What people and clinics actually do with ipamorelin (and what we can't tell you)

The line that governs everything below: there is no approved clinical dose for ipamorelin, and no human trial has ever tested the subcutaneous dose, route, or cycle that people actually use. Everything in this section is what people report doing in community forums and what wellness and anti-aging clinics publish. It is not a recommendation, it has not been validated, and it is the weakest tier of evidence on this page. One thing to keep firmly in mind as you read: people use ipamorelin chasing fat loss, muscle, and anti-aging, and none of those outcomes has been shown in a human. Reporting the dose someone uses is not the same as endorsing the result they are hoping for. We include the practice because pretending it doesn't exist doesn't make anyone safer. Understanding it, with the risks named, does.

What's commonly reported. Across peptide forums and clinic-published protocols the reported pattern is fairly consistent: a subcutaneous injection of roughly 100 to 300 micrograms, with 100 micrograms widely described as the per-pulse "saturation" point above which extra drug reportedly adds little growth hormone — a forum-derived figure, never tested for the subcutaneous route in any trial. The near-universal route is subcutaneous, drawn on an insulin syringe. Timing lore centers on before bed, to ride the body's largest natural growth-hormone pulse, and away from food, on the reasoning that the insulin from a meal blunts the growth-hormone release; the physiology behind the food-timing idea is plausible, but the claim that any particular timing is optimal is forum lore, not trial data. Frequency splits along goals: once a day at bedtime is the commonly reported pattern, while two-to-three-times-a-day dosing circulates in more bodybuilding-leaning circles, with no consensus that more is better. Cycles are described loosely, anywhere from eight weeks to several months, with clinics quoting twelve-to-sixteen-week blocks to "assess response" and no agreed off-duration.

The stack people reach for. The most-discussed pattern by far is ipamorelin combined with CJC-1295 (usually the no-DAC form), co-drawn into a single nightly shot, with the community defaulting to a 1:1 ratio and many clinics publishing a 1:2 (often 100 micrograms CJC to 200 micrograms ipamorelin). The reasoning people give is that the two act on different parts of the growth-hormone system, so they are described as complementary. Report that as what the practice claims, not as a settled fact: this pairing has never been tested as a combination in a human trial, so it is a clinic and community convention, not a validated protocol, and there is no human evidence it produces the body-composition results it is run for.

What the community itself flags. The forums are not naive about the downsides. The most commonly reported effects are water retention or mild puffiness, attributed to growth hormone's effect on fluid, and increased hunger, which users themselves frame as a paradox: ipamorelin works through the same appetite-driving ghrelin receptor as the hunger hormone, so a peptide taken for a leaner look can drive you to eat more, the very mechanism the animal data say can add fat. Numbness or tingling, a classic growth-hormone-axis effect, is reported less consistently. Injection-site irritation, headache, and dizziness also appear. Users flag the things this page has already named: no long-term human safety data, a theoretical cancer concern tied to stimulating the growth-hormone and IGF-1 axis, possible effects on blood sugar, and a strong warning to anyone with a cancer history to stay away. Many also treat the supply as the number-one risk, reconstituting with bacteriostatic water and demanding batch-specific third-party purity testing, a certificate of analysis, before using anything, precisely because the product is an unregulated research chemical. Manipulating your own growth-hormone axis is not a benign act, and the community knows it.

What we can't tell you, honestly. Several cautions about the numbers above. We could not read the primary forum threads directly, because Reddit blocks automated access, so these community figures reach us second-hand through clinic and vendor write-ups that summarize them, and that secondary path is itself a limitation. A large share of the clinic "protocols" online are published by businesses that sell the prescription or the product, and they repeat each other's numbers, so the apparent agreement is partly an echo chamber rather than independent confirmation. We also left out the vendor pages asserting precise muscle-gain or fat-loss percentages and "clinically proven" anti-aging outcomes: those lack any trial-grade basis, they read as marketing, and several looked fabricated, so we excluded them and are telling you we did. What survives is a fair sketch of what is commonly done, not evidence that any of it is safe, effective, or worth doing.

If you are going to explore it anyway, the harm-reduction version is straightforward: do it with a clinician who knows your history and can monitor your blood sugar and other labs, insist on a real certificate of analysis for the exact batch, keep the anti-doping ban in front of you if you compete, and understand that you are the experiment, because the human data that would tell you whether this does anything you want, or is safe over months, does not exist. And if the honest answer for your situation is "not worth it," that is a legitimate place to land.

What the evidence implies clinically

By Dr. Sam Walters, NMD, Medical Director

The pattern that matters most with ipamorelin is the gap between a number moving and a person getting better. Ipamorelin moves a number: it raises growth hormone for a short window, and that much is genuinely demonstrated in people. Whether that pulse turns into anything you would feel is a separate question, and the human evidence that it does is simply not there.

Look at the shape of the evidence and the implication is hard to miss: a clean laboratory story, one human study that measured only a hormone level, a single controlled trial against a real clinical outcome that failed, a row of rat studies standing in for everything else, and a standing ban in sport. The body regulates its own growth-hormone rhythm closely, and "more, on demand" is not an obvious improvement on that design. When the strongest animal data on body fat point toward more fat through appetite while the marketing promises the reverse, the safest reading for most people is "not yet," and that is the reading I would want a prescriber to pressure-test before anyone acts on it.

The honest close

For ipamorelin, the evidence supports a narrow, honest description and not much more: it transiently raises growth hormone in healthy adults, a biomarker effect, not a demonstrated benefit. Its only controlled human disease trial failed, it has never been approved, there are no human safety data for the way it is actually sold, and it is banned in sport. The bone, muscle, fat-loss, and anti-aging claims attached to it are, at best, rat data, and the closest animal evidence on body fat points the wrong way. For most people, the accurate read is "not yet," and for athletes it is "not at all."

We do not prescribe, and we do not recommend a dose for you. We report what is actually done in research and practice and synthesize the evidence so you can have an informed conversation with your clinician, and when the honest read is "not yet" or "probably not worth it for you," we say so.

This content is for informational purposes and is not medical advice. Consult a licensed practitioner before changing any therapeutic protocol.

We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.